23andMe Investor Presentation Deck
>>> >>> >>> >>>
Systematic, Scalable Research Platform Yields
Novel Drug Targets
Phenotypic Data
Genetic Data
10,000s of Genome-Wide Association Study (GWAS) Hits
Determine Disease Associated Genes and Directionality
Translational Research to Understand Mechanism
Identifying Druggable Targets
Phenome-Wide Association Studies (PheWAS) Reveal
Additional Indications and Potential Safety Concerns
Assessment of Unmet Need and
Competitive Landscape
Best Drug Targets
Wet lab validated targets progress through standard stages of research toward
the selection of preclinical lead molecules and clinical development
23andMe's database yields
thousands of GWAS hits
Advanced biology and medicinal
chemistry guide design of
optimal compounds from initial
targets
Phenotypic breadth provides
unique ability to uncover
potential safety issues or
possible indication expansions
Copyright © 2023 23andMe, Inc.
23andMe
36View entire presentation